Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Emory University
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Pfizer
Hoffmann-La Roche
MacroGenics
Herlev Hospital
University of California, San Diego
Thomas Jefferson University
Merck Sharp & Dohme LLC
BerGenBio ASA
Altor BioScience
University of Pennsylvania
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Istari Oncology, Inc.
Pierre Fabre Medicament
National Cancer Institute (NCI)
Pfizer
ADC Therapeutics S.A.
Parker Institute for Cancer Immunotherapy
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Pfizer
Eli Lilly and Company
Eisai Inc.
Takeda
Stanford University
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Massachusetts General Hospital
Hoffmann-La Roche
Herlev Hospital
Karyopharm Therapeutics Inc
H. Lee Moffitt Cancer Center and Research Institute
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Abramson Cancer Center at Penn Medicine
Pfizer
Pfizer
Bristol-Myers Squibb
Bristol-Myers Squibb
GlaxoSmithKline
Takeda
Immunocore Ltd
Merck Sharp & Dohme LLC
Eli Lilly and Company